Expression of p16(INK4A) and p14(ARF) in hematological malignancies

Leukemia

Volumn 13, Issue 11, 1999, Pages 1760-1769

  Taniguchi, T ^a   Chikatsu, N ^a   Takahashi, S ^b   Fujita, A ^c   Uchimaru, K ^d   Asano, S ^e   Fujita, T ^a   Motokura, T ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

^c Showa General Hospital   (Japan)

^d TEIKYO UNIVERSITY   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

Author keywords

ARF; INK4A; Leukemia; Lymphoma; Prognosis; RT PCR

Indexed keywords

MESSENGER RNA; PROTEIN; PROTEIN P14; PROTEIN P16; UNCLASSIFIED DRUG; CYCLIN D1; PROTEIN P14ARF; RETINOBLASTOMA PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BLAST CELL CRISIS; BLOOD; BLOOD DISEASE; BONE MARROW; CANCER SURVIVAL; CELL LINE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; GENE DELETION; GENE LOCUS; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MESSENGER RNA SYNTHESIS; METHYLATION; MYELOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; CELL CULTURE; DNA METHYLATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; CYCLIN D1; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P16; HEMATOLOGIC NEOPLASMS; HUMANS; LYMPH NODES; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PROGNOSIS; PROTEINS; RETINOBLASTOMA PROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 0032589692     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401557     Document Type: Article

References (50)

1. Sherr CJ. Tumor surveillance via the ARF-p53 pathway. Gene Dev 1998; 12: 2984-2991.
2. Sharpless NE, DePinho RA. The INK4A/ARF locus and its two gene products. Curr Opin Genet Dev 1999; 9: 22-30.
3. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-707.
4. Sherr CJ. G1 phase progression: cycling on cue. Cell 1994; 79: 551-555.
5. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G, Bartek J. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 1995; 375: 503-506.
6. ink4 requires functional retinoblastoma protein. Proc Natl Acad Sci USA 1995; 92: 6289-6293.
7. Li Y, Nichols MA, Shay JW, Xiong Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res 1994; 54: 6078-6082.
8. INK4/MTS1 tumuor suppressor gene product. EMBO J 1995; 14: 503-511.
9. CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol 1996; 16: 859-867.
10. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RR, Johnson BE, Skolnick MH. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436-440.
11. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368: 753-756.
12. Drexler HG. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 1998; 12: 845-859.
13. INK4/MTS1 gene transcript expressed in B-cell malignancies. Oncogene 1995; 11: 21-29.
14. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83: 993-1000.
15. Liggett W Jr, Sewell DA, Rocco J, Ahrendt SA, Koch W, Sidransky D. p16 and p16β are potent growth suppressors of head and neck squamous carcinoma cells in vitro. Cancer Res 1996; 56: 4119-4123.
16. ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998; 17: 5001-5014.
17. ARF. Cell 1997; 91: 649-659.
18. ARF encoding exons in T-cell acute lymphoblastic leukemia. Blood 1998; 91: 1016-1020.
19. Robertson KD, Jones PA. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol Cell Biol 1998; 18: 6457-6473.
20. Uchimaru K, Taniguchi T, Yoshikawa M, Asano S, Arnold A, Fujita T, Motokura T. Detection of cyclin D1 (bcl-1, PRAD1) over-expression by a simple competitive reverse transcription-polymerase chain reaction assay in t(11;14)(q13;q32)-bearing B-cell malignancies and/or mantle cell lymphoma. Blood 1997; 89: 965-974.
21. Taniguchi T, Fujita A, Takahashi S, Uchimaru K, Yoshikawa M, Asano S, Fujita T, Motokura T. Cyclin D1 overexpression detected by a simple competitive reverse transcription-polymerase chain reaction assay for lymphoid malignancies. Jpn J Cancer Res 1998; 89: 159-166.
22. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
23. Ponte P, Ng SY, Engel J, Gunning P, Kedes L. Evolutionary conservation in the untranslated regions of actin mRNAs: DNA sequence of a human beta-actin cDNA. Nucleic Acids Res 1984; 12: 1687-1696.
24. Hill HD, Straka JG. Protein determination using bicinchoninic acid in the presence of sulfhydryl reagents. Anal Biochem 1988; 170: 203-208.
25. Uchimaru K, Taniguchi T, Yoshikawa M, Fujinuma H, Fujita T, Motokura T. Growth arrest associated with 12-o-tetradecanoylphorbol-13-acetate-induced hematopoietic differentiation with a defective retinoblastoma tumor suppressor-mediated pathway. Leukemia Res 1998; 22: 413-420.
26. Raeymaekers L. A commentary on the practical applications of competitive PCR. Genome Res 1995; 5: 91-94.
27. Ogawa S, Hirano N, Sato N, Takahashi T, Hangaishi A, Tanaka K, Kurokawa M, Tanaka T, Mitani K, Yazaki Y, Hirai H. Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias. Blood 1994; 84: 2431-2435.
28. Filippini G, Griffin S, Uhr M, Eppenberger H, Bonilla J, Cavalli F, Soldati G. A novel flow cytometric method for the quantification of p53 gene expression. Cytometry 1998; 31: 180-186.
29. Farrell PJ, Allan GJ, Shanahan F, Vousden KH, Crook T. p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J 1991; 10: 2879-2887.
30. Cheng J, Haas M. Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol 1990; 10: 5502-5509.
31. Chow VT, Quek HH, Tock EP. Alternative splicing of the p53 tumor suppressor gene in the Molt-4 T-lymphoblastic leukemia cell line. Cancer Lett 1993; 73: 141-148.
32. Yamato K, Oka T, Hiroi M, Iwahara Y, Sugito S, Tsuchida N, Miyoshi I. Aberrant expression of the p53 tumor suppressor gene in adult T-cell leukemia and HTLV-l-infected cells. Jpn J Cancer Res 1993; 84: 4-8.
33. Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, Ishikawa F, Takaku F, Yazaki Y, Hirai H. Frequent mutations in the p53 gene in human myeloid leukemia cell lines. Blood 1992; 79: 2378-2383.
34. Bi S, Hughes T, Bungey J, Chase A, de Fabritiis P, Goldman JM. p53 in chronic myeloid leukemia cell lines. Leukemia 1992; 6: 839-842.
35. Wolf D, Rotter V. Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci USA 1985; 82: 790-794.
36. Kogawa K, Mogi Y, Morii K, Takimoto R, Niitsu Y. TGF-β and platelet. Jpn J Clin Hematol 1994; 35: 370-375.
37. Kawamura M, Ohnishi H, Guo SX, Sheng XM, Minegishi M, Hanada R, Horibe K, Hongo T, Kaneko Y, Bessho F, Yanagisawa M, Sekiya T, Hayashi Y. Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia. Leukemia Res 1999; 23: 115-126.
38. Martinez-Delgado B, Robledo M, Arranz E, Osorio A, García MJ, Echezarreta G, Rivas C, Benitez J. Hypermethylation of p15/ink4b/MTS2 gene is differentially implicated among non-Hodgkin's lymphomas. Leukemia 1998; 12: 937-941.
39. Ng MH, Chung YF, Lo KW, Wickham NW, Lee JC, Huang DP. Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood 1997; 89: 2500-2506.
40. INK4a gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 1998; 91: 2977-2984.
41. Villuendas R, Sánchez-Beato M, Martínez JC, Saez Al, Martinez-Delgado B, García JF, Mateo MS, Sanchez-Verde L, Benítez J, Martínez P, Piris MA. Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression. Am J Pathol 1998; 153: 887-897.
42. Geradts J, Andriko JW, Abbondanzo SL. Loss of tumor suppressor gene expression in high-grade but not low-grade non-Hodgkin's lymphomas. Am J Clin Pathol 1998; 109: 669-674.
43. Klangby U, Okan I, Magnusson KP, Wendland M, Lind P, Wiman KG. p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma. Blood 1998; 91: 1680-1687.
44. Nakamaki T, Kawamata N, Schwaller J, Tobler A, Fey M, Pakkala S, Lee YY, Kim BK, Fukuchi K, Tsuruoka N, Kahan J, Miller CW, Koeffler HP. Structural integrity of the cyclin-dependent kinase inhibitor genes, p15, p16 and p18 in myeloid leukaemias. Br J Haematol 1995; 91: 139-149.
45. INK4a MTS1 gene. Oncogene 1997; 15: 2475-2481.
46. INK4a/CDKN2 by illegitimate V(D)J recombinase activity in T-cell acute lymphoblastic leukemias. Blood 1997; 90: 3720-3726.
47. Garcia-Sanz R, Gonzalez M, Vargas M, Chillon MC, Balanzategui A, Barbon M, Flores MT, San Miguel JF. Deletions and rearrangements of cyclin-dependent kinase 4 inhibitor gene p16 are associated with poor prognosis in B cell non-Hodgkin's lymphomas. Leukemia 1997; 11: 1915-1920.
48. Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood 1997; 89: 272-280.
49. Elenitoba-Johnson KS, Gascoyne RD, Lim MS, Chhanabai M, Jaffe ES, Raffeld M. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 1998; 91: 4677-4685.
50. ink4a is associated with a poor prognosis in childhood acute lymphoblastic leukemia. Leukemia 1999; 13: 181-189.